American Century Companies’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-391,051
| Closed | -$26.6M | – | 2639 |
|
|
2022
Q3 | $26.6M | Buy |
391,051
+13,189
| +3% | +$727K | 0.02% | 575 |
|
|
2022
Q2 | $12.1M | Buy |
377,862
+25,527
| +7% | +$747K | 0.01% | 844 |
|
|
2022
Q1 | $12.2M | Sell |
352,335
-1,410
| -0.4% | -$42.2K | 0.01% | 849 |
|
|
2021
Q4 | $10.4M | Buy |
353,745
+11,720
| +3% | +$363K | 0.01% | 872 |
|
|
2021
Q3 | $8.71M | Sell |
342,025
-331
| -0.1% | -$9.73K | 0.01% | 882 |
|
|
2021
Q2 | $12M | Buy |
342,356
+134,684
| +65% | +$5.26M | 0.01% | 777 |
|
|
2021
Q1 | $8.46M | Buy |
207,672
+79,887
| +63% | +$3.67M | 0.01% | 816 |
|
|
2020
Q4 | $5.53M | Buy |
127,785
+42,459
| +50% | +$2.09M | ﹤0.01% | 864 |
|
|
2020
Q3 | $4.71M | Sell |
85,326
-9,141
| -10% | -$581K | ﹤0.01% | 811 |
|
|
2020
Q2 | $5.96M | Sell |
94,467
-6,367
| -6% | -$437K | 0.01% | 752 |
|
|
2020
Q1 | $5.15M | Sell |
100,834
-5,199
| -5% | -$348K | 0.01% | 721 |
|
|
2019
Q4 | $8.43M | Buy |
106,033
+40,715
| +62% | +$2.41M | 0.01% | 723 |
|
|
2019
Q3 | $3.17M | Buy |
65,318
+3,846
| +6% | +$200K | ﹤0.01% | 891 |
|
|
2019
Q2 | $3.23M | Buy |
61,472
+14,293
| +30% | +$821K | ﹤0.01% | 925 |
|
|
2019
Q1 | $2.5M | Sell |
47,179
-8,762
| -16% | -$431K | ﹤0.01% | 962 |
|
|
2018
Q4 | $2.3M | Sell |
55,941
-2,941
| -5% | -$110K | ﹤0.01% | 948 |
|
|
2018
Q3 | $2.24M | Sell |
58,882
-419
| -0.7% | -$18.6K | ﹤0.01% | 1010 |
|
|
2018
Q2 | $2.68M | Buy |
+59,301
| New | +$2.7M | ﹤0.01% | 968 |
|
Other funds holding GBT
American Century Companies's GBT Position: Q4 2022 in Review
American Century Companies sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 391,051 shares — an estimated $26.6M sold.
American Century Companies first reported a position in GBT in Q2 2018 and held it in 18 quarters. The position peaked at $26.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- American Century Companies reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- American Century Companies sold 391,051 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $26.6M.
- American Century Companies first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 18 quarters.
- American Century Companies's Global Blood Therapeutics, Inc. position peaked at $26.6M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on American Century Companies's 13F filing for Q4 2022, filed 13 Feb 2023.